Shelley Allen
Project Director II, Peptide Discovery Abbvie
Shelley Allen is an accomplished drug discovery leader with more than 25 years of experience in medicinal chemistry. She has a proven history of building and leading successful teams in both biotech and pharma, consistently delivering high-quality drug candidates with a strong sense of urgency. Shelley served as the Head of Drug Discovery at Nimble Therapeutics until its acquisition by AbbVie earlier this year. She now continues her impactful work at AbbVie, contributing to the discovery and development of peptide programs within the Immuno-Pharmacology & Peptide Discovery group.
Seminars
Practical Approaches to Characterize ADME & Design Translatable In Vitro & In Vivo PK/PD Studies with Jianzhong Wen
- What in vitro stability assays do you rely on early to triage candidates, and which have predicted in vivo best for your programs?
- Which permeability assays or systems have been most predictive for peptides in your experience?
- How much is needed to evaluate metabolism or transporter related DDI for peptide drugs?
Improving Permeating Agent Performance to Achieve Successful Peptide Oral Bioavailability with Shelley Allen
- How to use non-naturals to improve stability against proteases and other micro-environment challenges?
- How can we use half-life extension lipidation for permeating agents to improve bioavailability?
- What tissue properties or targets are important to consider for improved bioavailability?
